Hematopoietic stem cell transplantation (HSCT) is a cornerstone of modern medical practice, and can only be performed safely and effectively with appropriate transfusion medicine support. Patients undergoing HSCT often develop therapy-related cytopenia, necessitating differing blood product requirements in the pre-, peri-, and post-transplant periods. Moreover, ensuring optimal management for patients alloimmunized to human leukocyte antigens (HLA) and/or red blood cell (RBC) antigens, as well as for patients receiving ABO-incompatible transplants, requires close collaboration with transfusion medicine and blood bank professionals. Finally, as updated transfusion guidelines and novel blood product modifications emerge, the options available to the transplant practitioner continue to expand. Herein, we detail contemporary blood transfusion and transfusion medicine practices for patients undergoing HSCT.
CITATION STYLE
Adkins, B. D., Jacobs, J. W., Booth, G. S., Savani, B. N., & Stephens, L. D. (2024). Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review. Clinical Hematology International. Saabron Press. https://doi.org/10.46989/001c.94135
Mendeley helps you to discover research relevant for your work.